Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1330 of 5804
-
Supercharged immune cells take on tough ovarian cancers
Disease control Recruiting nowThis phase I trial tests the safety, side effects, best dose of MUC1-activated T cells in treating patients with ovarian cancer that has come back after a period of improvement (relapsed) or that remains despite treatment (resistant). T cells are infection fighting blood cells th…
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New hope for stomach cancer: experimental drug combo trial opens
Disease control Recruiting nowThis is a phase 1/2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of investigational agents with pembrolizumab and fluoropyrimidine chemotherapy for the first-line (1L) treatment of participants with locally advanced unresectable …
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New combo pill aims to tackle obesity and diabetes together
Disease control OngoingThe main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136 for chronic weight management alone or in combination with Tirzepatide across a wide dose range in participants with Type 2 Diabet…
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New flu prevention shot shows promise in large trial
Prevention CompletedThe purpose of this study is to evaluate the effectiveness of CD388 in preventing symptomatic laboratory-confirmed influenza infections, as compared to placebo, and to select a dose of CD388 that is effective in preventing the same, when administered as a single dose via 3 subcut…
Phase: PHASE2 • Sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Prevention
Last updated Jun 27, 2026 14:00 UTC
-
Brain zaps plus brain games show promise for dementia
Symptom relief Recruiting nowDementia is a prevalent condition with no known cure. It affects not only the person with dementia but also the family. This study will investigate the effects of applying different transcranial electrical stimulation (tES) waveforms to find the optimal stimulation when paired wi…
Phase: NA • Sponsor: University of Manitoba • Aim: Symptom relief
Last updated Jun 27, 2026 07:57 UTC
-
Magnetic surgery: a new tool against obesity and diabetes?
Disease control CompletedThe objective of the MagDI Italy Study is to evaluate the feasibility / performance, safety, and initial efficacy of the MagDI System in eligible participants who are indicated for a duodeno-ileal (small bowel) side-to-side anastomosis procedure for partial intestinal diversion (…
Phase: NA • Sponsor: GT Metabolic Solutions, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New depression drug candidate ABX-002 enters Mid-Stage trial
Symptom relief Recruiting nowThe goal of this clinical trial is to learn if ABX-002 added to an existing antidepressant treatment will benefit depression symptoms in adults with moderate to severe major depressive disorder who have had an inadequate response to their antidepressant. This is a double-blind, …
Phase: PHASE2 • Sponsor: Autobahn Therapeutics, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 08:12 UTC
-
Could a daily pill replace insulin for kidney transplant patients?
Disease control Recruiting nowBackground: Post-transplant hyperglycaemia occurs frequently in renal transplant recipients within the first two weeks after transplantation. Standard-of-care is primarily based on insulin treatment with the adherent risk of hypoglycaemia and weight gain. Semaglutide produces an …
Phase: PHASE4 • Sponsor: Rigshospitalet, Denmark • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New Ketamine-Like drug could ease nerve pain without the high
Symptom relief Recruiting nowThe goal of this randomized double blind three way (1:1:1) cross over clinical trial is to evaluate the effectiveness and duration of analgesia of a single infusion of (2R,6R)-HNK 0.5mg/kg compared with ketamine 0.5mg/kg and saline with a 5-week interval between treatments on pai…
Phase: PHASE1, PHASE2 • Sponsor: Rush University Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 08:08 UTC
-
New injection could help nasal polyp sufferers avoid surgery
Disease control OngoingThe goal of this clinical trial is to learn if GR1802 works to treat severe chronic rhinosinusitis with nasal polyps (CRSwNP) in adults. It will also learn about the safety of GR1802. The main questions it aims to answer are: 1. Does GR1802 reduce the need for surgery and system…
Phase: PHASE3 • Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New shot aims to stop the maddening itch of prurigo nodularis
Symptom relief Recruiting nowThis trial was designed to evaluate the efficacy and safety of SHR-1819 injection in patients with Prurigo Nodularis.
Phase: PHASE2, PHASE3 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 12:25 UTC
-
Peer power: new study aims to boost HIV med adherence in women
Disease control Recruiting nowThe goal of this combination Type 1 hybrid and observational study is to evaluate the impact of a peer delivered intervention of acceptance and commitment therapy (ACT) + exercise + social support to address the substance (ab)use, violence, and AIDS/HIV (SAVA) to improve medicati…
Phase: NA • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New scan could sharpen liver cancer detection
Diagnosis Recruiting nowThis prospective, single-center study evaluates the clinical utility of F18-Piflufolastat (PSMA) PET/CT when added to conventional cross-sectional imaging for patients with suspected or confirmed hepatocellular carcinoma (HCC). The study aims to determine whether PSMA PET/CT impr…
Sponsor: VA Office of Research and Development • Aim: Diagnosis
Last updated Jun 28, 2026 00:00 UTC
-
Could a popular Weight-Loss drug help people with rare genetic obesity?
Disease control Recruiting nowRare genetic forms of obesity, so called monogenic obesity are linked to alteration in energy balance involving hypothalamic pathways. More than 60 genes encoding for proteins located in the hypothalamic leptin/melanocortin pathway have been described in the French National Prot…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug could help High-Risk patients get Life-Saving transplants
Disease control Recruiting nowThis research is being done to investigate the safety and effectiveness of Darzalex Faspro (daratumumab and hyaluronidase-fihj) (a monoclonal antibody that targets plasma cells that make antibodies) and whether it can lower donor specific antibodies (DSA) levels to low enough lev…
Phase: EARLY_PHASE1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Glow-in-the-Dark dye could help surgeons spot hidden prostate cancer
Diagnosis CompletedThis study is being done to compare how much using Cytalux™ (pafolacianine) with NIR (Near InfraRed) fluorescent imaging improves the detection of malignant (growing in an uncontrolled way) tissue in adult subjects undergoing prostatectomy and lymph node dissection for biopsy con…
Phase: PHASE2 • Sponsor: Indiana University • Aim: Diagnosis
Last updated Jun 27, 2026 13:02 UTC
-
New pill takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThe goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. T…
Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New digital tool aims to stop pregnancy pelvic pain from becoming a lifelong problem
Prevention Recruiting nowThe overall aim is to educate women to handle common pregnancy-related pain experiences to facilitate healthy life-long physical activity habits and prevent chronic pain. Our developed WOMENinMOTION model with person-centred preventions and interventions focused on management of…
Phase: NA • Sponsor: Vastra Gotaland Region • Aim: Prevention
Last updated Jun 26, 2026 14:24 UTC
-
New drug targets Hard-to-Treat cancers with genetic flaw
Disease control Recruiting nowThe main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants alone or in combination with other anticancer agents. In addition, with locally advanced or metastatic solid tumors with a BRG1 (Brahma-related gene 1…
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New combo therapy targets tough blood cancers
Disease control Recruiting nowThe purpose of this research is to gather information on the safety and effectiveness determining maximum tolerated dose (MTD) of ruxolitinib in combination with ivosidenib in IDH1-mutated advanced-phase Ph-negative MPNs while evaluate the efficacy of ruxolitinib in combination w…
Phase: PHASE1 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC